The article reviews the role of pyroptosis in diabetic cardiomyopathy (DCM), a significant cardiovascular complication of diabetes. Pyroptosis, a form of programmed cell death characterized by an inflammatory response, is emerging as a key player in DCM pathogenesis. The review highlights the molecular mechanisms of pyroptosis, particularly the involvement of the NLRP3 inflammasome, and its impact on various cell types in the heart, including cardiomyocytes, macrophages, fibroblasts, and endothelial cells. It discusses how chronic inflammation, driven by metabolic disturbances such as hyperglycemia and hyperinsulinemia, triggers pyroptosis, leading to cardiac dysfunction and remodeling. The article also explores potential therapeutic strategies targeting pyroptosis and the NLRP3 inflammasome, including hypoglycemic drugs, inhibitors of NLRP3, and non-coding RNAs. While significant progress has been made, the exact mechanisms and therapeutic interventions for DCM remain areas of ongoing research.The article reviews the role of pyroptosis in diabetic cardiomyopathy (DCM), a significant cardiovascular complication of diabetes. Pyroptosis, a form of programmed cell death characterized by an inflammatory response, is emerging as a key player in DCM pathogenesis. The review highlights the molecular mechanisms of pyroptosis, particularly the involvement of the NLRP3 inflammasome, and its impact on various cell types in the heart, including cardiomyocytes, macrophages, fibroblasts, and endothelial cells. It discusses how chronic inflammation, driven by metabolic disturbances such as hyperglycemia and hyperinsulinemia, triggers pyroptosis, leading to cardiac dysfunction and remodeling. The article also explores potential therapeutic strategies targeting pyroptosis and the NLRP3 inflammasome, including hypoglycemic drugs, inhibitors of NLRP3, and non-coding RNAs. While significant progress has been made, the exact mechanisms and therapeutic interventions for DCM remain areas of ongoing research.